Amylyx Pharmaceuticals just delivered a blockbuster update: their drug avexitide slashed severe hypoglycemic events by 55% in a Phase Three trial for post-bariatric hypoglycemia — a dangerous blood sugar crash affecting 8% of gastric bypass patients. The LUCIDITY trial, involving 78 participants, exceeded regulatory benchmarks and medical experts’ expectations, with no serious side effects reported — just mild diarrhea. Avexitide works differently than popular GLP-1 drugs by blocking insulin overproduction in the pancreas. Co-CEOs called it a “home run,” and FDA fast-track approval is on track for late 2026, with potential launch in 2027. Acquired via bankruptcy earlier this year, Amylyx remains financially cautious despite recent losses — but this could be their breakthrough moment for patients and investors alike.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
